Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company’s novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025. On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026. Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care